A group of affiliated entities led by Luxor Capital Group, LP filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common shares in Golar LNG Ltd as of a triggering event dated November 2, 2026.
ContextLogic Holdings Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 9, 2026, reporting condensed consolidated financial results as a successor entity following a business combination completed in late February 2026.
Mereo BioPharma Group plc filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting a net cash position of $26.1 million and a widening accumulated deficit.
Quanterix Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting total revenues of $34,974 thousand for the third quarter and $104,295 thousand for the nine months ended September …
SS&C Technologies Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the completion of a $1,200,000,000 aggregate principal amount offering of 2.75% Convertible Senior Notes due 2031, with the transaction closing on November 6, 2026.
Sonoco Products Company filed a Form 8-K on November 9, 2026, disclosing the planned retirement of President and CEO R. Howard Coker effective December 31, 2026, the appointment of Ernest D. Haynes III as his successor, and a retention award for Chief Financial Officer …
Innovative Industrial Properties, Inc. filed a Form 8-K on November 9, 2026, disclosing amendments to its existing equity distribution agreements that add the company's 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program.
Cellebrite DI Ltd. filed an announcement on November 9, 2026, notifying analysts and investors that the call-in number for its third-quarter 2026 financial results conference call had been updated, while all other details for the November 12, 2026 event remained unchanged from the October …
A Schedule 13G was filed on November 9, 2026, by The K2 Principal Fund, L.P. and three affiliated entities disclosing beneficial ownership of 241,100 Class A Ordinary Shares of Newbury Street II Acquisition Corp as of November 4, 2026.
Vir Biotechnology, Inc. filed a Form 8-K on November 9, 2026, disclosing topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial and expanded Week 96 data from the Phase 2 SOLSTICE study, both evaluating elebsiran and tobevibart in adults with chronic hepatitis …